Malign Karaciğer Tümörlerinde Perkütan Etanol Enjeksiyonu ve Kriyoterapi
Özet
Perkütan ablasyon, cerrahi rezeksiyona uygun olmayan primer hepatoselüler karsinom (HCC) ve karaciğer metastazlarının tedavisinde etkin bir alternatif yöntemdir. Bu yöntemler arasında öne çıkan perkütan etanol enjeksiyonu (PEE), hücresel dehidrasyon ve protein denatürasyonu yoluyla tümör nekrozunu indükleyen, düşük maliyetli ve düşük komplikasyon oranına sahip kimyasal bir uygulamadır. Enerji bazlı modalitelerin riskli olduğu hassas bölgelerde tercih edilen PEE, genellikle tam yanıt için birden fazla seans gerektirir. Diğer bir önemli yöntem olan kriyoablasyon ise argon ve helyum gazları kullanarak lezyon etrafında buz küresi oluşturup tümör nekrozu sağlar. Görüntüleme yöntemleriyle (US, BT, MRG) gerçek zamanlı izlenebilmesi, büyük damarlara zarar vermemesi ve daha az ağrıya yol açması kriyoablasyonun başlıca avantajlarındandır. Her iki tedavinin başarısı ve lokal nükslerin takibi, işlem sonrasında yapılan Doppler US, kontrastlı BT ve dinamik MRG tetkikleriyle hassas bir şekilde değerlendirilmektedir.
Percutaneous ablation is an effective alternative treatment for primary hepatocellular carcinoma (HCC) and liver metastases in patients unsuitable for surgical resection. Among these modalities, percutaneous ethanol injection (PEI) is a cost-effective, low-complication chemical method that induces local tumor necrosis through cellular dehydration and protein denaturation. Preferred in sensitive locations where energy-based techniques pose risks, PEI often requires multiple sessions to achieve a complete response. Another significant method, cryoablation, utilizes argon and helium gases to form an ice ball around the lesion, leading to tumor cell death. Its primary advantages include real-time monitoring via imaging techniques (US, CT, MRI), minimal impact on adjacent large blood vessels, and lower post-procedural pain. The therapeutic success and early detection of local recurrence for both interventions are meticulously evaluated during follow-up using color Doppler US, contrast-enhanced CT, and dynamic MRI scans.
Referanslar
Jemal A, Bray F, Center MM et al. Global cancer statistics. CA Cancer J Clin 2011;61:69–90.
Hodgson HJ. Primary hepatocellular carcinoma. Br J Hosp Med 1983;29:240, 246, 250 passim.
Dusheiko GM, Hobbs KE, Dick R, Burroughs AK. Treatment of small hepatocellular carcinomas. Lancet 1992;340:285–288.
Burroughs A, Hochhauser D, Meyer T. Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum. Lancet Oncol 2004;5:409–418.
Llovet JM, Ricci S, Mazzaferro V. et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378–390.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.J. Hepatol. 2018, 69, 182–236.
Peng, ZW, Zhang, YJ, Chen, MS et al. Radiofrequency Ablation With or Without Transcatheter Arterial Chemoembolization in the Treatment of Hepatocellular Carcinoma: A Prospective Randomized Trial. J. Clin. Oncol. 2013, 31, 426–432.
Ahmed M. Solbiati L. Brace CL et al. Image-guided Tumor Ablation: Standardization of Terminology and Reporting Criteria -A 10-Year Update. Radiology 2014, 273, 241–260.
Rhim H, Lee, MH, Kim Y et al. Planning Sonography to Assess the Feasibility of Percutaneous Radiofrequency Ablation of Hepatocellular Carcinomas. Am. J. Roentgenol. 2008, 190, 1324–1330.
Lee MW, Kim YJ, Park, HS et al. Targeted Sonography for Small Hepatocellular Carcinoma Discovered by CT or MRI: Factors Affecting Sonographic Detection. Am. J. Roentgenol. 2010, 194, W396–W400.
Dong Y, Wang WP, Gan Y et al. Radiofrequency ablation guided by contrast-enhanced ultrasound for hepatic malignancies: Preliminary results. Clin. Radiol. 2014, 69, 1129–1135.
Asvadi NH, Anvari A, Uppot RN et al. CT-Guided Percutaneous Microwave Ablation of Tumors in the Hepatic Dome: Assessment of Efficacy and Safety. J. Vasc. Interv. Radiol. 2016, 27, 496–502.
Hoffmann R, Rempp H, Keßler DE et el. MR-guided microwave ablation in hepatic tumours: Initial results in clinical routine. Eur. Radiol. 2016, 27, 1467–1476.
Rempp H, Loh H, Hoffmann R et al. Liver lesion conspicuity during real-time MR-guided radiofrequency applicator placement using spoiled gradient echo and balanced steady-state free precession imaging. J. Magn. Reson. Imaging 2013, 40, 432–439.
Lencioni R, Cioni D, Crocetti L et al. Early-Stage Hepatocellular Carcinoma in patients with Cirrhosis: Long-term Results of Percutaneous Image-guided Radiofrequency Ablation. Radiology 2005, 234, 961–967.
Li, M, Yu X, Liang P et al Ultrasound-guided percutaneous microwave ablation for hepatic malignancy adjacent to the gallbladder. Int. J. Hyperth. 2015, 31, 579–587.
Festi D, Monti F, Casanova S et al. Morphological and biochemical effects of intrahepatic alcohol injection in the rabbit. J Gastroenterol Hepatol 1990;5:402-406
Mazziotti A, Grazi GL, Gardini A, et al. An appraisal of percutaneous treatment of liver metastases Liver. Transpl. Surg.4 (1998), 271-275.
Shiina S, Teratani T, Obi S et al. Percutaneous ethanol injection therapy for liver tumors. Eur J Ultrasound. 2001 Jun;13(2):95-106.
Fujimoto T. The experimental and clinical studies of percutaneous ethanol injection therapy (PEIT) under ultrasonography for small hepatocellular carcinoma Acta. Hepatol. Jpn. 29 (1988), 52-59
Goletti O, DeNegri F, Pucciarelli M, et al Subcutaneous seeding after percutaneous ethanol injection of liver metastasisRadiology, 183 (1992), 785-786
Koda M, Murawaki Y, Idobe Y et al. Is choledocholithiasis a late complication of nonresectional therapies for hepatocellularcarcinoma? Hepatogastroenterology, 46 (1999), 3091-3094.
Kawano M. An expenmental study of percutaneous absolute ethanol therapy for small hepatocellular carcinoma: effects of absolute ethanol on the healthy canine liver. Gastroenterologica Japanica, 1989;24:663-669
Ravikumar TS, Kane R, Cady Bi et al. A 5-Year study of cryosurgery in the treatment of liver tumors. Arch Surg. (1991);126:1520–1524.
McCarthy T, Kuhn JA. Cryotherapy for liver tumors. Oncology. (1998);12:979–993.
Niu LZ, Li JL, Xu KC. Percutaneous Cryoablation for Liver Cancer. J Clin Transl Hepatol. 2014;2(3):182-188.
Adam R, Hargreaves GM, Meriggi F, et al. Percutaneous cryosurgery of irresectable liver tumors. In: Holzheimer RG, Mannick JA, editors. Surgical Treatment: Evidence-Based and Problem-Oriented. Munich: Zuckschwerdt; 2001.
Thacker PG, Callstrom MR, Curry TB et al. Palliation of Painful Metastatic Disease Involving Bone With Imaging-Guided Treatment: Comparison of Patients’ Immediate Response to Radiofrequency Ablation and Cryoablation. Am. J. Roentgenol. 2011, 197, 510–515.
Littrup PJ, Ahmed A, Aoun HD et al. CT-guided percutaneous cryotherapy of renal masses. J Vasc Interv Radiol 2007;18: 383–392.
Littrup PJ, Freeman-Gibb L, Andea A et al. Cryotherapy for breast fibroadenomas. Radiology 2005;234:63–72.
Sabel MS. Cryo-immunology: a review of the literature and proposed mechanisms for stimulatory versus suppressive immune responses. Cryobiology 2009;58:1–11.
Ladd AP, Rescorla FJ, Baust JG et al. Cryosurgical effects on growing vessels. Am Surg 1999;65:677–682.
Arciero CA, Sigurdson ER. Liver-directed therapies for patients with primary liver cancer and hepatic metastases. Curr Treat Options Oncol 2006;7:399–409.
Chen HW, Cui WZ, Zhang HX. Ultrasound-guided minimally invasive targeting argon-helium cryoablation in the treatment of hepatic carcinoma. Zhongguo Shi Yong Wai Ke Za Zhi 2008;28:637–646.
Pearson AS, Izzo F, Fleming RY et al. Intraoperative radiofrequency ablation or cryoablation for hepatic malignancies. Am J Surg 1999;178:592–599.
Yang Y, Wang C, Lu Y et al. Outcomes of ultrasound-guided percutaneous argon-helium cryoablation of hepatocellular carcinoma. J Hepatobiliary Pancreat Sci 2012;19:674–684.
Wong WS, Patel SC, Cruz FS et al. Cryosurgery as a treatment for advanced stage hepatocellular carcinoma: results, complications, and alcohol ablation. Cancer 1998;82:1268–1278.
Sandomirsky M, Crifasi JA, Long C et al. Case report of fatal complication in prostatic cryotherapy. First reported death due to argon gas emboli. Am J Forensic Med Pathol 2012;33:68–72.
Castroagudin JF, Delgado M, Martinez SM et al. Doppler ultrasonography for the assessment of tumor necrosis after percutaneous ethanol injection prior to liver transplantation as adjuvant therapy of hepatocellular carcinoma. Transplant Proc. 2005 Apr;37(3):1493-5.
Yoshikawa J, Matsui O, Kadoya M et al. Hepatocellular carcinoma: CT appearance of parenchymal changes after percutaneous ethanol injection therapy. Radiology. 1995 Jan;194(1):107-11.
Kubota Y, Nakano T, Seki T, et al. Validity of MR imaging for monitoring effects of percutaneous ethanol injection for HCC Hepatogastroenterology, 36 (1989), 262-265.
Bartolozzi C, Lencioni R, Caramella D et al. Treatment of hepatocellular carcinoma with percutaneous ethanol injection: evaluation with contrast-enhanced MR imaging Am. J. Roentgenol., 162 (1994), 827-31
Ishii H, Okada S, Sato T et al. Effect of percutaneous ethanol injection for postoperative recurrence of hepatocellular carcinoma in combination with transcatheter arterial embolizationHepatogastroenterology, 43 (1996), 644-650
Hamad GG, Neifeld JP. Biochemical, hematologic, and immunologic alterations following hepatic cryotherapy. Semin Surg Oncol 1998;14:122–128.
Langenhoff, BS, Oyen WJGi Jager G et al. Efficacy of Fluorine-18- Deoxyglucose Positron Emission Tomography on Detecting Tumor Recurrence After Local Ablative Therapy for Liver Metastases: A Prospective Study. J Clin Oncol, 2002;20:4453-4458.
King J, Glenn D, Morris DL. Computed tomography changes following cryotherapy for hepatic cancer. Australas Radiol. 1997 May;41(2):112-7.
Rong G, Bai W, Dong Z et al. Long-term outcomes of percutaneous cryoablation for patients with hepatocellular carcinoma within Milan criteria. PLoS One. 2015 Apr 7;10(4):e0123065.
